{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"19"}],"units":"Participants"}],"description":"An AE was defined as any untoward medical occurrence in a participant administered a study treatment which did not necessarily have to have a causal relationship with this treatment. An AE could be any unfavourable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of study treatment, whether or not considered related to the study treatment. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a pre-existing condition that was temporally associated with the use of study treatment, was also an AE.","groups":[{"description":"Participants received pembrolizumab 200 mg intravenously (IV) every 3 weeks (Q3W) in combination with pemetrexed 500 mg/m\\^2 IV and cisplatin 75 mg/m\\^2 IV for 4-6 cycles, followed by pembrolizumab 200 mg/m\\^2 IV monotherapy Q3W for up to 35 cycles from the first dose of the study treatment (approximately 2 years). Each cycle was 21 days.","id":"OG000","title":"Pembrolizumab + Pemetrexed + Cisplatin"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All participants who received at least 1 dose of study intervention","reportingStatus":"POSTED","timeFrame":"Up to approximately 2 years","title":"Number of Participants Discontinuing Study Treatment Due to an AE","type":"PRIMARY","unitOfMeasure":"Participants"}